Moreover, five myxomas had mutation at codon 201 of GNAS. Neither myxomas nor myxofibrosarcomas had mutations of KRAS codon 12/13 or TP53, nor was there any significant difference in FOS expression between intramuscular myxoma and grade I myxofibrosarcoma. This evidence concerns the gene KRAS and myxoma.